Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Tuberculosis
Conditions
Pulmonary Tuberculosis
Trial Timeline
Jan 1, 2008 → Feb 1, 2014
NCT ID
NCT00864383About Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin is a phase 3 stage product being developed by Sanofi for Pulmonary Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00864383. Target conditions include Pulmonary Tuberculosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00864383 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Tuberculosis